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A B S T R A C T
Aims: The non-genomic (prompt) actions of sex steroids on pregnant uterine contractility are not fully explored
yet, the aim of our study was to clarify such effects of 17-β estradiol (E2), progesterone (P4) and testosterone (T)
on late (22-day) pregnant uterine contractions together with the signaling pathways in rats in vitro.
Methods: The uterine effects of sex steroids on KCl-stimulated contractions were examined in the presence of
genomic pathway blocker actinomycin D and cycloheximide, sex hormone receptor antagonists (flutamide,
fulvestrant, mifepristone) and also after removing the endometrium. The modifications in uterine G-protein
activation and cAMP levels were also detected.
Results: T and E2 both relaxed the uterine contractions in the concentration range of 10−8–10−3 M with an
increase in the activated G-protein and cAMP levels of the uterus, while P4 was ineffective. Cycloheximide,
actinomycin D, antagonist for T and E2 were not able to modify the responses along with the endothelium
removal. Mifepristone blocked the relaxing effects of T and E2 and reduced the activation of G-protein and the
formation of cAMP.
Significance: T and E2 can inhibit KCl-stimulated contractions in the late pregnant uterus in high concentrations
and in a non-genomic manner. Their actions are mediated by a G-protein coupled receptor that can be blocked
by mifepristone. A single and high dose of T or E2 might be considered in premature contractions, however,
further preclinical and clinical studies are required for the approval of such a therapeutic intervention.
1. Introduction
Sex hormones mediate a wide range of developmental processes and
physiological functions, especially in reproductive organs. Sex hor-
mones can even influence pregnant uterine contractility; their ratio may
be an important key in the parturition process. Progesterone is well-
known as a pro-gestational hormone reducing uterine contractility and
maintaining pregnancy [1]. On the other hand, estrogens increase the
contraction of the pregnant uterus and contribute to the parturition
process [2]. However, the effect of testosterone (T) on pregnancy has
not exactly been clarified yet, it is presumed to increase the rate of
miscarriage [3].
The classical signaling pathway of steroids is the “genomic
pathway”. Steroids first pass the membrane, bind to specific steroid
receptors and make a ligand-receptor complex, which goes into the
nucleus; then, by binding to the hormone response element or func-
tional proteins like nuclear factor kappa B, they alter gene transcription
and protein synthesis [4]. This action has a significant gap time be-
tween the drug administration or the secretion of hormones and the
desired effect.
However, there is prompt action for all types of steroids which oc-
curs immediately (without a significant gap time) called “non-genomic
pathway”. One of the first studies about the non-genomic action of sex
steroids demonstrated that immediately after the administration of 17-β
estradiol (E2) to ovariectomized rat, the level of uterine cyclic adeno-
sine monophosphate (cAMP) was doubled [5]. Several other studies
showed that sex hormones exert a variety of prompt functional effects
on different tissues, such as cancer cells in breast [6], pituitary glands
[7], sperms [8], nerve cells [9] and many other targets.
It is known that the results of the non-genomic action can be the
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same as or even different from the effects mediated through the
genomic pathway. E.g. in the cardiovascular system and diabetes mel-
litus, the outcome of both signaling pathways is the same [10–13], but
in breast cancer cell lines, their actions can be the opposite [14].
Since the prompt actions of sex steroids on uterine contractility are
not fully explored yet, the aim of our study was to clarify the non-
genomic effects of E2, progesterone (P4) and T on late (22-day) preg-
nant uterine contractions together with the signaling pathways in rats
in vitro.
2. Materials and methods
2.1. Animals
Housing, handling, and mating of animals were performed as de-
scribed previously [15]. In brief, 22-day-pregnant Sprague Dawley
(SPRD) rats were chosen for the experiment, they were housed in the
animal facility of the Department of Pharmacology and Pharma-
cotherapy, Faculty of Medicine, University of Szeged under controlled
temperature, humidity and light (20–23 °C and 40–60% and 12 h light/
dark regime, respectively). The animals were kept on a standard Al-
tromin 1324 rodent pellet diet (Charles-River Laboratories, Sulzfeld,
Germany), with tap water available ad libitum.
Mature female rats (180–200 g) in estrus cycle were chosen by va-
ginal impedance with Estrus Cycle Monitor (Fine Science Tools, Foster
City, CA, USA), the selected females and stud male rats (240–260 g)
were placed separately in special breeding cages separated by an au-
tomated movable gate. The gate was pulled up at 4 am and the mating
was possible within 4–5 h. To confirm the intercourse, the native va-
ginal smear or copulation plugs were evaluated. The positive cases were
housed in separate cages and considered as on the first day of preg-
nancy.
This project was approved by the Hungarian Ethical Committee for
Animal Research (Permission number: IV./13071/2016). The animals
were treated in accordance with the European Communities Council
Directive (86/609/ECC) and the Hungarian Act for the Protection of
Animals in Research (Article 32 of Act XXVIII).
2.2. Isolated organ bath contractility studies
The experimental protocol is shown in Fig. 1. The animals were
terminated in a carbon dioxide chamber and the uterus samples were
cut from both sides of the uterine horns. After cleaning from connective
and adipose tissue, 3–4-mm dissected uterine tissues were tied with silk
thread and mounted vertically in isolated organ bath filled with 10 ml
de Jongh buffer consisting of 137 millimolar (mM) NaCl, 3 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 12 mM NaHCO3, 4 mM NaH2PO4, 6 mM
glucose, the pH was adjusted between 7.35 and 7.40 with constant
temperature (37 °C) and with carbogen (95% O2 + 5% CO2) support.
Tissues were attached to a gauge transducer (SG-02; MDE GmBH.,
Heidelberg, Germany), with initial resting tension of 1.5 g, the con-
tractions were measured, recorded and analyzed with a SPEL Advanced
ISOSYS Data Acquisition System (MDE GmBH., Heidelberg, Germany).
The tissues were washed periodically every 15 min during the 1-h
equilibrium incubation period.
To achieve a satisfactory rhythmic contraction response, KCl
(25 mM) was added to each chamber for 7 min. Each steroid was added
in a cumulative way (T, E2, P4) (10−8–10−3 M) every 5 min.
Concentration-response curves were plottedagainst the KCl-stimulated
contraction response and the effects of steroids were expressed in per-
centage change.
In another set of experiments, uterine tissues were pre-treated with
cycloheximide (10−6 M), a protein synthesis inhibitor and actinomycin
D (10−6 M), a transcriptional inhibitor for 2 steroids (E2 and testos-
terone) separately for 30 min. Tissues were pre-treated with the fol-
lowing steroid hormone receptor antagonists for 10 min before KCl
stimulation: fulvestrant (10−6 M) for E2, flutamide (10−6 M) for T and
mifepristone 10−6 M for all types of steroids.
Finally, the endometrium of the uterine tissues was removed by
scraping and the experiments were repeated to observe the effect of the
steroids on the myometrium. The experimental protocol of the isolated
organ bath study is shown in Fig. 1.
The samples for each experiment were collected from both sides of
the uterine horns of 2 animals (8 rings/experiment) and repeated at
least 3 times for each individual set of experiments (n = 60).
Fig. 1. The isolated organ baths experimental protocol, the 1-h incubation period, 7-min KCl stimulation and cumulative dose treatment from 10−8- 10−3 M in 5-min
interval time were the same for all experiments; (1) intact or endometrium removed pregnant uterus samples treated with T, E2 and P4; (2) pregnant uterine samples
with pre-treatment with actinomycin D and cycloheximide (c) for 30 min then treated with T and E2 treatment; (3) 10-min pre-treatment with steroid receptor
antagonist (a): fulvestrant 10−6 M for E2, flutamide 10−6 M for T and mifepristone 10−6 M for all steroid treatments, then treatment with T, E2 and P4.
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2.3. [35S]GTPγS studies
The [35S]GTPγS binding experiments protocol was carried outby the
previously described method [16] with modifications. Briefly, the
pregnant uterine tissue samples from SPRD rats (n= 5) were collected
and stored at −70 °C before preparation. The samples were ground,
then homogenized with 20 volumes (W/V) of ice-cold Tris-EDTA buffer
(composed of 10 mm Tris–HCl, 1 mM EDTA, 0.6 mMMgCl2, and 0.25 M
sucrose, pH 7.4) with Ultra-Turrax® (IKA-Werke GmbH & Co. KG,
Staufen in Breisgau, Germany) homogenizer in an ice bath for 2 × 30 s,
after that suspended with 4-layer gauze filter, then centrifuged at
40000g for 20 min at 4 °C. Later the pellets were suspended in 5 vo-
lumes of buffer. The protein content was measured by a Nanodrop™
2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, US)
and diluted to 10 mg/ml sample.
Samples were pre-incubated in the final volume of 900 μl of Tris-
EGTA buffer (pH 7.4) composed of 50 mM Tris-HC, 1 mM EGTA, 3 mM
MgCl2, 100 mM NaCl, containing 20 mbq/0.05 cm3 [35S]GTPγS
(0.05 nm) without or with mifepristone (10−6 M) for 15 min in 30 °C.
After that, E2 and T were added separately to each tube in an increasing
dose (10−8–10−4) for 20 min. The total binding was measured without
drugs. Nonspecific binding was evaluated by 10 μm unlabeled GTPγs
and differences from total binding (basal activity).After the incubation
time, by using vacuum filtration (through Whatman GF/B filters with
Brandel M24R Cell harvester), the bound and free [35S]GTPγS were
separated. The filters were washed 3 times in ice-cold buffer (pH 7.4),
the radioactivity of the filters was measured in Ultimagold™ MV scin-
tillation cocktail with Packard Tricarb 2300TR liquid scintillation
counter. The experiment was arranged in triplicates and repeated three
times.
2.4. Cyclic AMP studies
The cyclic AMP (cAMP) level in uterine tissues was measured by a
commercial cAMP Enzyme Immunoassay Kit (Cayman Chemical, USA).
Uterine tissue samples of 22-day-pregnant SPRD rats (n = 8) were in-
cubated in an organ bath filled with de Jongh buffer. The samples were
incubated without or with mifepristone (10−6 M) for 10 min, and KCl
25 mM was added for further 7 min. Then E2 and T or control (vehicle)
were added in 2 different doses (10−4 and 10−6 M) for 5 min, and
forskolin (10−5 M) was added for another 10 min. Finally, the samples
were snap frozen by liquid nitrogen and stored at −70 °C for sample
Fig. 2. Effects of testosterone (T) on KCl-induced (25 mM) uterine contractions at concentrations of 10−8–10−4 M in a cumulative manner. Contraction was induced
in the uterine rings prepared from rats on gestational day 22. Each figure is a representative record. (a) Effect of T after stimulation with KCl, (b) after 30 min of
actinomycin D and cycloheximide pre-treatment, (c) after endometrium removal, (d) with pre-treatment with flutamide 10−6 M and (e) with pre-treatment with
mifepristone 10−6 M.
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preparation. During the preparation frozen tissues were weighed, pul-
verized, mixed and homogenized with 10 volumes of 5% trichloroacetic
acid (TCA) aqueous solution (0–4 °C), and centrifuged at 1500g for
15 min. The supernatants were mixed with 5 volumes of water-satu-
rated ether and shaken in 10 s to extract TCA from it, the ether su-
pernatant was removed, discarded and this process was repeated 3
times. Finally, after removing all the ether by heating, the liquid sam-
ples were stored at −70 °C till the cAMP assay was carried out. The
amounts of cAMP were expressed in nmol/mg tissue.
2.5. Drugs and chemicals
1,3,5-Estratriene-3,17β-diol (E2), 4-pregnene-3,20-dion (P4), 17β-
Hydroxy-3-oxo-4-androstene (T), cycloheximide, actinomycin D, mife-
pristone and flutamide were all purchased from Sigma-Aldrich,
Budapest, Hungary. Fulvestrant (Falsoldex) 250 mg/ml injection was
purchased from AstraZeneca Pharmaceutical, Budapest, Hungary.
Forskolin was purchased from Tocris, Norderstedt, Germany.
All the drugs were dissolved in ethanol 97%, the highest percentage
of the solvent did not exceed 0.087% V/V.
2.6. Statistical analysis
Concentration-response curves were fitted by the analysis of the
areas under curve (AUC) of contractility responses. Statistical analysis
was carried out by the Prism 8.0 (GraphPad Software Inc. San Diego,
CA, USA) computer program using ANOVA Dunnett's test. The Emax and
EC50 values were calculated based on AUC. The results are presented as
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Fig. 3. Effects of T on pregnant uterine contractions stimu-
lated with KCl (25 mM) and pre-treated with actinomycin D
and cycloheximide, and after endometrium removal (a), and
with pre-treatment with flutamide or mifepristone (b) pre-
sented by percent of relaxation. **: p < 0.01; ***:
p < 0.001; ActD, actinomycin D; Chx, cycloheximide; Endo,
endometrium; Flu, flutamide; Mif, mifepristone; T, testos-
terone.
Table 1
Changes in the Emax and EC50 values of the uterine relaxing effect of T alone, with pre-treatment with actinomycin D and cycloheximide and mifepristone and also
after the removal of the endometrium in the 22-day-pregnant rat. ActD, actinomycin D; Chx, cycloheximide; Endo, endometrium; Flu, flutamide; Mif, mifepristone; T,
testosterone.
T T+ ActD+ Chx T+ FLU T+ Mif Endo removal
Emax (% ± S.E.M) 72.9 ± 7.8 77.4 ± 2.4 62.4 ± 8 41.9 ± 7.2 70.2 ± 2.7
EC50 (M) 3.0e−005 3.8e−005 3.3e−005 5.8e−005⁎⁎⁎ 1.0e−005
⁎⁎⁎ p < 0.001.
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Fig. 4. Effect of T (10−8–10−4 M) on [35S]GTPγS binding with or without pre-
treatment with mifepristone. Mifepristone reduced the T-induced increase in
[35S]GTPγS binding. Basal activity (100%) refers to the level of [35S]GTPγS
binding without any substances. **: p < 0.01; Mif, mifepristone; T, testos-
terone.
Table 2
Changes in the [35S]GTPγS binding induced by T alone and with pre-incubation
with mifepristone in the 22-day-pregnant rat uteri. Mif, mifepristone; T, tes-
tosterone.
T T+ Mif
Emax (% ± S.E.M) 230 ± 9.3 166 ± 7.2⁎⁎
EC50 (M) 7e-007 1.2e-006
⁎⁎ p < 0.01.
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the mean ± SEM.
3. Results
3.1. Testosterone
3.1.1.1. Isolated organ bath study. T elicited a relaxing effect especially
at high concentrations (10−5–10−3 M) and reached 70% relaxation of
the uterus (Figs. 2a, 3a, Table 1). The presence of cycloheximide and
actinomycin D (Figs. 2b, 3b, Table 1), the removal of the endometrium
(Figs. 2c, 3b, Table 1) or even flutamide did not modify the relaxing
effect of T. However, mifepristone shifted the T concentration-response
curve to the right and reduced its maximal inhibitory effect. In the
subsequent experiments investigating the signaling pathway, we
measured the T action alone or in the presence of mifepristone. The
interventions (endometrium removal) and drug treatments
(actinomycin D, cycloheximide, flutamide) with non-significant
modifications were omitted from further studies.
3.1.1.2. [35S]GTPγs binding assay studies. T increased the [35S]GTPγS
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Fig. 5. Change in the level of uterine cAMP in the presence of T alone and after
pre-treatment with mifepristone. The uterine cAMP level was expressed in ng/
mg tissue. *: p < 0.05 **: p < 0.01; ***: p < 0.001; Mif, mifepristone; T,
testosterone.
Fig. 6. Effects of 17 β-estradiol (E2) on KCl-induced uterine contractions at concentrations of 10−8 to 10−4 M in a cumulative manner. Contraction was induced by
KCl (25 mM) in the uterine rings prepared from rats on gestational day 22. Each figure is a representative record. (a) Effect of E2 after 7 min of stimulation with KCl,
(b) after 30 min of actinomycin D and cycloheximide pre-treatment, (c) after endometrium removal, (d) with pre-treatment with fulvestrant 10−6 M and (e) with pre-
treatment with mifepristone 10−6 M.
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binding in a concentration dependent manner. The pre-treatment with
mifepristone reduced specific binding and shifted the curve to the right,
indicating less activation of G-proteins (Fig. 4 and Table 2).
3.1.1.3. cAMP study. The pregnant uterus cAMP level was raised by T
compared to the control at both low and high concentrations (10−6 and
10−4(). Moreover, the pre-treatment with mifepristone significantly
reduced the uterine cAMP levels by T (Fig. 5).
3.2. 17-β estradiol
Isolated organ bath study: E2 relaxed pregnant uterine contractions,
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Fig. 7. Effect of E2 on pregnant uterus tissue stimulated with
KCl (25 mM) in the presence of actinomycin D and cyclo-
heximide (a), and with pre-treatment with fulvestrant or
mifepristone, and after endometrium removal (b) presented
by percent of relaxation. *:p < 0.05 **: p < 0.01; ***:
p < 0.001; ActD, actinomycin D; Chx, cycloheximide; E2,
17-β estradiol; Mif, mifepristone; Ful, fulvestrant.
Table 3
Changes in the Emax and EC50 values of the uterine relaxing effect of E2 alone, with pre-treatment with actinomycin D and cycloheximide, fulvestrant and mife-
pristone and after removing the endometrium. ActD, actinomycin D; Chx, cycloheximide; E2, 17-β estradiol; Ful, fulvestrant; Mif, mifepristone.
E2 E2+ ActD +Chx E2 + Ful E2+ Mif Endo removal
Emax (% ± S.E.M) 67.8 ± 2.8 71.7 ± 3.8 54.8 ± 2.9 15.4 ± 5.5⁎⁎⁎ 51.3 ± 4.6
EC50 (M) 9.5e−006 1.3e−005 5.3e−006 6.7e−006 4.6e−006
⁎⁎⁎ p < 0.001.
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Fig. 8. The effect of E2 (10−8–10−4 M) on [35S]GTPγS binding with or without
pre-treatment with mifepristone. Mifepristone reduced the E2-induced increase
in [35S]GTPγS binding. Basal activity (100%) refers to the level of [35S]GTPγS
binding without substance. **: p < 0.01; E2, 17-β estradiol; Mif, mifepristone.
Table 4
Changes in the [35S]GTPγS binding effect of E2 alone and with pre-incubation
with mifepristone in the 22-day-pregnant rat. E2, 17-β estradiol; Mif, mife-
pristone.
E2 E2+ Mif
Emax (% ± S.E.M) 196.3 ± 7.7 155 ± 4.5⁎⁎
EC50 (M) 7.1e−007 8.5e−007
⁎⁎ p < 0.01.
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Fig. 9. Changes in the level of cAMP in the presence of E2 alone (10−6 and
10−4 M) and with pre-treatment with mifepristone expressed in ng/mg tissue.
*: p < 0.05 **: p < 0.01; E2, 17-β estradiol; Mif, mifepristone.
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at the highest concentration (10−4 M), the inhibition was 70% (Figs. 6,
7a, Table 3). Actinomycin D and cycloheximide (Figs. 6b, 7a, Table 3),
the removal of the endometrium (Figs. 6c, 7a, Table 3) or even pre-
treatment with fulvestrant, (Figs. 6d, 7b, Table 3) did not influence the
effect of E2. In contrast, pre-treatment with mifepristone reduced the
relaxing effect of E2, but did not modify the EC50 value (Figs. 6e, 7b,
Table 3). In the subsequent experiments investigating the signaling
pathway, we measured the E2 action alone or in the presence of mi-
fepristone. The interventions (endometrium removal) and drug treat-
ments (actinomycin D, cycloheximide, flutamide) with non-significant
modifications were omitted from further studies.
3.2.1.1. [35S]GTPγS binding assay studies. The [35S]GTPγS binding was
increased by E2 in a concentration dependent manner, which was
reduced by mifepristone (Fig. 8 and Table 4).
3.2.1.2. cAMP study. E2 increased the level of cAMP in the uterine
tissue compared to the control in high concentrations, while it had no
effect in a low dose. The pre-treatment with mifepristone reduced the
high E2 concentration-induced cAMP increase (p < 0.01), but
mifepristone had no action in the case of low E2 concentration (Fig. 9).
3.3. Progesterone
P4 had a negligible effect on KCl-stimulated uterine contractions.
The presence of mifepristone did not modify its action (Figs. 10, 11,
Table 5). Since the relaxing effect of P4 was missing, we did not in-
vestigate it further.
4. Discussion
The non-genomic action of sex steroids on different tissues, espe-
cially on smooth muscles from different organs, has been investigated in
several studies. It was proved that E2 and P4 had a vasorelaxant action
through a non-genomic pathway. Studies on rat arterial beds showed
that E2 induced vascular relaxation [17]. The same results were found
on the arterial tissues in human [18,19] lamb [20], monkey [21] and
mice [12]. On the contrary, the non-genomic action of E2 induced
hyperreactivity and contraction on tracheal smooth muscles [22]. Ad-
ditionally, E2 elicited non-genomic vasoconstriction in mice, which led
to the reduction of skin cooling action [23]. The non-genomic smooth
muscle relaxing effect of T was proved in human coronary arteries [24],
umbilical arteries [25,26], peripheral vasculature of rats [27] and even
in the trachea of guinea pigs [28,29]. However, a comparative in-
vestigation of the non-genomic effect of sex hormones on pregnant
uterine contractions has not been carried out yet.
Therefore, we aimed to investigate the effects of the 3 basic sex
hormones (E2, P4 and T) on pregnant uterine contractions on the last
day of pregnancy in rats in vitro. E2 and T elicited a significant re-
duction in uterine contractions, while P4 was ineffective. The exposure
time of the uterine tissues to the sex hormones was less than 30 min,
which is considered to be too short to initiate the genomic response
[30]. We also proved this, since the blockade of the genomic pathway
by the RNA transcription inhibitor actinomycin D and the protein
synthesis inhibitor cycloheximide did not modify the effects of E2 or T.
Subsequently, the removal of the endometrium did not modify the sex
hormone effects either, so we also proved that the relaxation effects of
E2 and T has a myometrial site of action. Surprisingly, both E2 and T
had a remarkable relaxing effect (approximately 70% inhibition). Al-
though such an action of T was described earlier on human and preg-
nant rat uteri [31] [32], such a result about E2 has not been published
yet. In contrast, E2, T and P4 were reported as ineffective on both
pregnant rat and human myometrial contractions induced by oxytocin
in vitro [33], but in that study the sex steroids were used in lower
concentrations (below 10−6 M), while we applied them in 10−4 or
10−3 M as the highest concentrations. Thus, the high concentrations
can explain why we could detect quite a strong relaxing effect with T
and E2. The other surprise was the ineffectiveness of P4 on pregnant
contractions considering its clinical use against premature contractions
Fig. 10. Effects of progesterone (P4) on KCl-induced (25 mM) uterine contractions at concentrations of 10−8 to 10−4 M in a cumulative manner. Uterine rings were
gained from rats on gestational day 22. Each figure is a representative record. (a) Effect of progesterone after stimulation with KCl and (b) with pre-treatment with
mifepristone 10−6 M.
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Fig. 11. Effect of P4 on pregnant uterus smooth muscle contractions stimulated
by KCl, alone and in the presence of mifepristone. Mif, mifepristone; P4, pro-
gesterone.
Table 5
Changes in the uterine-contracting effect of P4 alone and in the presence of
mifepristone. P4; progesterone. Mif, mifepristone;
P4 P4 + Mif
Emax (% ± S.E.M) 16.8 ± 6.9 20.6 ± 2.6
EC50 (M) 1.2e007 1.2e−007
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in threatening preterm birth [34], although in that case it is applied as a
preventive agent. Our result suggests that there is no prompt relaxing
action of P4 on pregnant uterine contractions. Similarly, earlier studies
did not find any non-genomic relaxing effect for P4 either [35], al-
though a synthetic P4 derivative, dydrogesterone was found to inhibit
the pregnant myometrial contractions by the inhibition of voltage de-
pendent Ca-channels [33]. Some other experiments found that P4 had
an ability to relax human non-pregnant or pregnant uterine tissues in
high dose [36–38] which findings are virtually in conflict of our results.
However, the findings may be a result of genomic feature of P4 since
the P4 incubation period in both reported studies were more than 1 h.
The specific receptor antagonists of sex hormones (flutamide for T
and fulvestrant for E2) did not reduce their actions, which is further
evidence that the genomic pathway is not involved in the relaxing ef-
fects of T and E2. Surprisingly, the actions of T and E2 were mifepris-
tone sensitive, their maximum effects were reduced significantly by the
compound. This suggests that mifepristone generally inhibits the non-
genomic target of sex steroids for uterus relaxation, which is possibly
independent of its progesterone and glucocorticoid receptor inhibitory
action. The G protein coupled estrogen receptor (GPER or GPR30),
which is coupled to Gs protein and enhances the intracellular cAMP
level, has already been identified as a target of sex steroids in several
tissues [39,40] as well as in human myometrium [41]. In our
[35S]GTPγS binding and cAMP measurements we proved a significant
increase in G-protein and cAMP levels after stimulation by T and E2,
and their effects could be inhibited by mifepristone. The previously
reported signaling pathway for putative sex steroid membrane re-
ceptors involves phospholipase, kinase [42], calcium [43] and other
second messengers such as IP3 or cAMP [44]. It is also possible that the
activation of a G protein receptor by rising cAMP regulates the voltage-
gated ion channels (e.g. BKCa and KV) [26] and the intracellular calcium
regulation [11,22]. Our results suggest that T and E2 possibly activate
GPR30 and mifepristone might be a competitive antagonist on this re-
ceptor.
5. Conclusion
T and E2 can significantly inhibit KCl-stimulated contractions in the
late pregnant uterus in high concentrations and in a non-genomic
manner. Their actions are mediated by a G-protein coupled receptor
(possibly GPR30) that can be blocked by mifepristone. However, P4
seems to be inefficient as a non-genomic relaxant of pregnant uteri.
Based on our results, a single and high dose of T or E2 might be con-
sidered in premature contractions, however, further preclinical and
clinical studies are required for the approval of such a therapeutic in-
tervention.
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